Introduction
Immune evasion is considered the hallmark of cancers (1) . Strategies that restore the capacity of the immune system to recognize and eliminate malignant cells have produced clinical benefits. However, due to a dearth of predictive biomarkers for patient stratification, only one-third of all patients are responsive to treatment (2) . Immune evasion by tumor tissues has been the major bottleneck in the development of therapeutically effective anticancer strategies. The prominent mechanisms by which tumors evade immune attack include the evolution of tumor cell variants that are resistant to immune effectors and the progressive formation of an immune suppressive microenvironment within the tumor that impedes the infiltration of antitumor effector cells. Great emphasis has been placed on understanding the function of tumor-intrinsic somatic heterogeneity or the tumor-induced microenvironment in evading immune surveillance, but the role played by tumor-extrinsic, host-specific genetic heterogeneity in modulating the antitumor immune response is poorly understood and remains challenging to address.
An attribute common to all cancers is the presence of numerous cell types, including bone marrow-derived inflammatory cells, lymphocytes, fibroblastic cells, and the extracellular matrix composed of collagen and proteoglycans. Importantly, of diverse assemblages of tumor cell infiltrates, cytotoxic and regulatory T lymphocytes within the tumors are often the crucial factors that determine the outcome of anticancer therapy (3, 4) . For example, the increased T cell numbers, particularly an increased ratio of CD8/FOXP3 + regulatory T cells (Tregs) within the tumor microenvironment (TME), predict a favorable therapeutic response, whereas severe lymphopenia negatively impacts the chemo-and immunotherapy response (5) . It is well recognized that while the host immune system can recognize and reject cancerous cells, it can also mold the somatic heterogeneity of tumors by assisting in the generation of immune-resistant tumor variants (6) . Various mechanisms, such as immunoediting, exist whereby primary tumor rejection is rendered compromised and ineffective by the inhibition of cytotoxic CD8 T cell infiltration or viability in the TME. An imminent question thus arises: can individual-specific heritable genetic variants regulate immune homeostasis such that immune surveillance is impaired in a host-dependent manner irrespective of the nature of oncogenic onslaught? Here, we attempted to address this question by dissecting the tumorextrinsic immunological function of signal transducer and activator of transcription 3-enhancing (STAT3-enhancing) germline receptor variants in shaping the TME. Many of the genes that have been studied to modulate immune responses have variants that occur in frequencies ranging from rare (<1%) to common (>10%) in the general population. There are approximately 907.3 million SNPs catalogued in the Single Nucleotide Polymorphism Database (dbSNP) build 150 (Feb 3, 2017) , and it is practically impossible to systemically evaluate all polymorphic SNPs in the human genome through association studies alone. Here, we demonstrate for the first time that by examining the cancer-associated germline receptor variants that enhance the amplitude of STAT3 signaling
Immune evasion and the suppression of antitumor responses during cancer progression are considered hallmarks of cancer and are typically attributed to tumor-derived factors. Although the molecular basis for the crosstalk between tumor and immune cells is an area of active investigation, whether host-specific germline variants can dictate immunosuppressive mechanisms has remained a challenge to address. A commonly occurring germline mutation (c.1162G>A/rs351855 G/A) in the FGFR4 (CD334) gene enhances signal transducer and activator of transcription 3 (STAT3) signaling and is associated with poor prognosis and accelerated progression of multiple cancer types. Here, using rs351855 SNP-knockin transgenic mice and Fgfr4-knockout mice, we reveal the genotype-specific gain of immunological function of suppressing the CD8/ CD4
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Results and Discussion
To identify all SNP variants that create membrane-proximal tyrosine-based STAT3 docking motifs, we performed a comprehensive computational analysis of all publicly available human genotyping data sets, namely, the 1,000 Genomes, Phase 3 (12), Figure 3B ). To some degree, the suppression was dependent on interleukin 10 (IL10), since the presence of neutralizing IL10 mAb in the cocultures, particularly A and B) showed no significant differences between the 2 genotypes. However, the numbers of CD8 + T cells were significantly decreased in the thymus, blood, lymph nodes, and spleen of . The suppressed levels of CD8 + T cells in Fgfr4 rs351855-A/A genotypes appeared as a systemic trait, since lower levels were also found in the nonlymphoid organs analyzed, including parenchymal tissues such as lung and mammary tissue pads ( Figure 2B ). On the other hand, the quantification of FOXP3 + CD25 + Tregs revealed a significant increase in Tregs under unchallenged homeostasis conditions in healthy adult mice ( Figure 2C and Supplemental Figure 6C) . Concordantly, the levels of Foxp3 and Il10 transcripts were significantly elevated, whereas the levels of Cd8 mRNA transcripts were decreased in the spleens of + cells in the thymus and spleen of 6-to 8-week-old Fgfr4 +/+ and Fgfr4 -/-mice measured by flow cytometry. Data represent the percentages of total single-cell suspensions (mean ± SEM, n = 5-6, NS = not significant). Statistical comparisons of groups were performed using 2-way ANOVA and Tukey's t test with multiple comparisons. All flow cytometry measurements on WT and mutant cohorts of mice were performed on the same day.
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jci.org Volume 128 Number 5 May 2018 models (GEKIMM) for breast and lung cancers (see Methods). As expected, although the tumor incidence rates in both the disease models were not dramatically altered, the tumor burden and progression were significantly elevated in animals expressing the minor allele variant rs351855-A (25) . Flow cytometric analysis of the age-and sexual phenotype-matched cohorts of knockin transgenic mouse models for breast (26) cohorts of GEKIMMs for both breast ( Figure 4E ) and lung (Figure 4F) cancers. Although STAT3 signaling is considered crucial for T helper cell differentiation during immune challenges, we did not observe any significant differences between the 2 genotypes in the transgenic disease models for breast or lung cancer. The proportions of differentiated CD4 + T cell subsets (namely, Th1, Th2, and Th17) in spleens and tumors of GEKIMM for lung cancer (Supplemental Figure 10) and GEKIMM for breast cancer (Supplemental Figure 11) were not altered. We propose that the in higher CD8/Treg ratios (32:1, 16:1), led to similar suppressive capacities by both genotypes (Supplemental Figure 9) . IL10 signals primarily by inducing pSTAT3 at Y705 via the STAT3 docking sites in the cytoplasmic domains of IL10R (23) . Therefore, we conclude that the synergistic action of the rs351855-A allele with IL10 signaling explains the enhanced suppressive functions of Tregs in Fgfr4 rs351855-A/A -knockin mice. Thus, under healthy homeostatic conditions, a germline-encoded increase in basal pSTAT3 (Y705) levels in Tregs leads to a systemic decrease in the CD8/Treg ratio. This finding suggests that alterations in the CD8/Treg ratio in vivo are mechanistically linked to the presence of the minor allele rs351855-A and are not determined by the activity of FGFR4. The STAT3-enhancing gain of function by the minor allele of rs351855 is independent of the extracellular or intracellular domains of FGFR4 and is mediated by the membrane-proximal STAT3 docking site in the juxtamembrane segment of the FGFR4 p.Gly388Arg variant (24) . We therefore attribute the genotype-dependent systemic suppression of the CD8/Treg ratio to the pleiotropic effect of STAT3-enhancing gain of function by the SNP rs351855-A. Disruption of the STAT3 membrane-recruitment event by the depletion of FGFR4 in the Fgfr4 -/-mice abolished the SNP-specific gain of the immunological phenotype ( Figure 3C ).
To determine whether STAT3-enhancing germline variants mediate a tumor-extrinsic immune evasive pleiotropic phenotype, we generated genetically engineered SNP-knockin mouse Tregs and CD8 T cells were mixed at different ratios and stimulated using mouse T-activator CD3/ CD28 Dynabeads. Three days after stimulation, the percentage of suppression was calculated as described in Methods. Data are representative of 3 independent experiments. For each experiment, cells were isolated from a group of 5 mice of either genotype, and each mixed ratio was cocultivated in replicates of 5 wells (mean ± SEM, NS = not significant, *P < 0.05, **P < 0.01, ***P < 0.001). Statistical comparisons of groups were performed by 2-way ANOVA using Sidak's multiple comparisons test. (C) Graphic summary illustrating the SNP-specific gain of immunological function by the minor allele (NC_000005.10:g.177093242G>A) of the rs351855 SNP. The genotype-dependent phenotype is abolished in the FGFR4-deficient mice and is indistinguishable from the WT FGFR4-variant-expressing cohorts, indicative of enhanced rs351855 G>A-variant-specific STAT3 signaling in lymphoid organs. differences in these subsets may be notable in the mouse models for inflammation-induced cancers. Collectively, through data from knockin mice, knockout mice, and genetically engineered knockin mouse models for lung and breast cancers, our study illustrates a pleiotropic effect of cancer-associated STAT3-enhancing germline variants in shaping some aspects of the TME (Supplemental Figure 12) . Hence, we conclude that the immune evasive phenotype of the TME can be determined by the pleiotropic functions of individual-specific germline variants in the immune cells. In this regard, cancer-associated germline recep- 
